Advertisement
Screener

Spero Therapeutics, Inc. (SPRO) Restricted Cash and Cash Equivalents, Noncurrent

Spero Therapeutics, Inc. Restricted Cash and Cash Equivalents, Noncurrent

Spero Therapeutics, Inc. (SPRO) had Restricted Cash and Cash Equivalents, Noncurrent of $50.00 thousand as of 2017-12-31, per its 10-K filed 2019-03-14.

Discontinued › Balance Sheet › Assets › Assets, Noncurrent

us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2019-03-14

  • 2017-12-31: Restricted Cash and Cash Equivalents, Noncurrent $50.00K.
  • 2017-09-30: Restricted Cash and Cash Equivalents, Noncurrent $50.00K.
  • 2016-12-31: Restricted Cash and Cash Equivalents, Noncurrent $50.00K.
Period endRestricted Cash and Cash Equivalents, Noncurrent
2017-12-31$50.00K
10-K · filed 2019-03-14
2017-09-30$50.00K
10-Q · filed 2017-12-14
2016-12-31$50.00K
10-K · filed 2018-04-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cingulate Inc. (CING)United States$0.073B-2.64
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
Yarrow Bioscience, Inc. (YARW)United States$0.070B
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17